Journal Article
. 2008 Jan; 3(4):251-255.
doi: 10.1159/000148914.

Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives

Marc L Citron 1 
  • PMID: 21076605
  •     21 References
  •     18 citations


The dose intensity of adjuvant chemotherapy for breast cancer is an important predictor of clinical outcome. Dose-dense chemotherapy increases the dose intensity of the regimen by delivering standard-dose chemotherapy with shorter intervals between the treatment cycles. The rationale for dose-dense therapy stems from the Norton-Simon hypothesis: Sequential, consecutive dosing of chemotherapy using single or a combination of agents increases the dose density over alternating dosing, improving results. Supporting adjuvant studies, such as C9741, and the ensuing clinical experience indicate an improved disease-free and overall survival. Dosedense adjuvant chemotherapy improves clinical outcomes without increasing toxicity.

Dose-Dense Therapy.
Michael Untch, Jonas Bergh, +4 authors, Günter Steger.
Breast Care (Basel), 2008 Jan 01; 3(2). PMID: 21373218    Free PMC article.
A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity.
W Hryniuk, E Frei, F A Wright.
J Clin Oncol, 1998 Sep 17; 16(9). PMID: 9738586
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
Donald A Berry, Constance Cirrincione, +9 authors, Eric P Winer.
JAMA, 2006 Apr 13; 295(14). PMID: 16609087    Free PMC article.
Highly Cited.
Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.
G Bonadonna, M Zambetti, P Valagussa.
JAMA, 1995 Feb 15; 273(7). PMID: 7837388
Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma.
C Mayers, T Panzarella, I F Tannock.
Cancer, 2001 Jun 20; 91(12). PMID: 11413512
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
I Craig Henderson, Donald A Berry, +16 authors, Larry Norton.
J Clin Oncol, 2003 Mar 15; 21(6). PMID: 12637460
Highly Cited.
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.
G Bonadonna, P Valagussa, +2 authors, C Brambilla.
N Engl J Med, 1995 Apr 06; 332(14). PMID: 7877646
Highly Cited.
The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens.
Richard Simon, Larry Norton.
Nat Clin Pract Oncol, 2006 Aug 09; 3(8). PMID: 16894366
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group.
K D Miller, A O'Neill, +2 authors, G W Sledge.
Ann Oncol, 2011 Aug 09; 23(2). PMID: 21821545    Free PMC article.
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
Marco Venturini, Lucia Del Mastro, +11 authors, Paolo Bruzzi.
J Natl Cancer Inst, 2005 Dec 08; 97(23). PMID: 16333028
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25.
B Fisher, S Anderson, +18 authors, N Wolmark.
J Clin Oncol, 1999 Nov 05; 17(11). PMID: 10550131
The importance of dose intensity in the outcome of chemotherapy.
W M Hryniuk.
Important Adv Oncol, 1988 Jan 01;. PMID: 3042601
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
Eric P Winer, Donald A Berry, +14 authors, Larry Norton.
J Clin Oncol, 2004 Jun 01; 22(11). PMID: 15169793
Evolving concepts in the systemic drug therapy of breast cancer.
L Norton.
Semin Oncol, 1997 Aug 01; 24(4 Suppl 10). PMID: 9275000
Impact of dose-intense chemotherapy on the development of permanent drug resistance.
A J Coldman, J H Goldie.
Semin Oncol, 1987 Dec 01; 14(4 Suppl 4). PMID: 3686044
HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients.
L Del Mastro, P Bruzzi, +11 authors, Marco Venturini.
Br J Cancer, 2005 Jun 23; 93(1). PMID: 15970926    Free PMC article.
Dose density in breast cancer: a simple message?
Nancy U Lin, Rebecca Gelman, Eric P Winer.
J Natl Cancer Inst, 2005 Dec 08; 97(23). PMID: 16333021
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Chau Dang, Monica Fornier, +17 authors, Clifford Hudis.
J Clin Oncol, 2008 Mar 08; 26(8). PMID: 18323546
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.
D R Budman, D A Berry, +8 authors, E Frei.
J Natl Cancer Inst, 1998 Aug 27; 90(16). PMID: 9719081
Highly Cited.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
Dose: a critical factor in cancer chemotherapy.
E Frei, G P Canellos.
Am J Med, 1980 Oct 01; 69(4). PMID: 6999898
Highly Cited.
A way forward on the medically appropriate use of white cell growth factors.
Thomas J Smith, Bruce E Hillner.
J Clin Oncol, 2012 Mar 01; 30(14). PMID: 22370327    Free PMC article.
The dynamics of drug resistance: a mathematical perspective.
Orit Lavi, Michael M Gottesman, Doron Levy.
Drug Resist Updat, 2012 Mar 06; 15(1-2). PMID: 22387162    Free PMC article.
Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine.
Andreia de Albuquerque, Sepp Kaul, +2 authors, Nikos Fersis.
Breast Care (Basel), 2012 May 04; 7(1). PMID: 22553466    Free PMC article.
Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.
József Zsiros, Laurence Brugieres, +17 authors, International Childhood Liver Tumours Strategy Group (SIOPEL).
Lancet Oncol, 2013 Jul 09; 14(9). PMID: 23831416    Free PMC article.
Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.
Geralyn E Waters, Patricia Corrigan, Mandy Gatesman, Thomas J Smith.
J Oncol Pract, 2013 Aug 15; 9(4). PMID: 23942922    Free PMC article.
Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial.
Gianluca Tomasello, Wanda Liguigli, +9 authors, Rodolfo Passalacqua.
Gastric Cancer, 2013 Nov 28; 17(4). PMID: 24282019
Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.
D Lu, A Joshi, +5 authors, J Y Jin.
CPT Pharmacometrics Syst Pharmacol, 2014 May 23; 3. PMID: 24850445    Free PMC article.
Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administration.
Graham M Wheeler, Michael J Sweeting, +2 authors, Ying Kuen K Cheung.
Stat Med, 2016 Feb 20; 36(2). PMID: 26891942    Free PMC article.
Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature.
Mattea Reinisch, Beyhan Ataseven, Sherko Kümmel.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051390    Free PMC article.
Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
Tobias Meißner, Adam Mark, +12 authors, Michael Forster.
Cold Spring Harb Mol Case Stud, 2017 Jul 07; 3(4). PMID: 28679691    Free PMC article.
Adipocyte and lipid metabolism in cancer drug resistance.
Yihai Cao.
J Clin Invest, 2019 Jul 03; 129(8). PMID: 31264969    Free PMC article.
Highly Cited. Review.
Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer.
Benjamin B Mull, J Andrew Livingston, +3 authors, Khandan Keyomarsi.
Br J Cancer, 2020 Jan 17; 122(6). PMID: 31942030    Free PMC article.
Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer.
Francesca Parisi, Maria Grazia Razeti, +7 authors, Matteo Lambertini.
Clin Med Insights Oncol, 2020 Jul 11; 14. PMID: 32647477    Free PMC article.
Cardiac involvement in disseminated diffuse large B-cell lymphoma, successful management with chemotherapy dose reduction guided by cardiac imaging: A case report and review of literature.
Rabah Al-Mehisen, Maha Al-Mohaissen, Hisham Yousef.
World J Clin Cases, 2019 Feb 02; 7(2). PMID: 30705895    Free PMC article.
Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates.
Fernando Kude de Almeida, Daniela Dornelles Rosa.
Breast Care (Basel), 2019 Feb 26; 13(6). PMID: 30800040    Free PMC article.
Doxorubicin Improves Cancer Cell Targeting by Filamentous Phage Gene Delivery Vectors.
Effrosyni Tsafa, Kaoutar Bentayebi, +7 authors, Amin Hajitou.
Int J Mol Sci, 2020 Oct 30; 21(21). PMID: 33114050    Free PMC article.
Case report of long-term survival with metastatic triple-negative breast carcinoma: Treatment possibilities for metastatic disease.
Ben Man-Fai Chue, Bryce Douglas La Course.
Medicine (Baltimore), 2019 Apr 23; 98(16). PMID: 31008982    Free PMC article.
A Diels-Alder polymer platform for thermally enhanced drug release toward efficient local cancer chemotherapy.
Nanami Fujisawa, Masato Takanohashi, +4 authors, Mitsuhiro Ebara.
Sci Technol Adv Mater, 2021 Jul 06; 22(1). PMID: 34220340    Free PMC article.